Advances in immunotherapy for refractory thyroid carcinoma
10.3760/cma.j.cn321828-20200604-00220
- VernacularTitle:难治性甲状腺癌免疫治疗进展
- Author:
Chengcheng DU
1
;
Zairong GAO
Author Information
1. 华中科技大学同济医学院附属协和医院核医学科、分子影像湖北省重点实验室，武汉 430022
- Keywords:
Thyroid neoplasms;
Immunotherapy;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2021;41(8):496-500
- CountryChina
- Language:Chinese
-
Abstract:
The poor prognosis of refractory thyroid cancer is the critical factor affecting the survival of patients with thyroid cancer. At present, multi-kinase inhibitors, surgery, particle implantation and other therapeutic methods are commonly used in clinical practice, which can improve the prognosis of patients to some extent, but the overall efficacy is still unsatisfactory. In recent years, immunotherapy has shown high efficacy, safety and reliability in the treatment of many tumors. In this article, the mechanism, current situation, method and prospect of immunotherapy in patients with refractory thyroid cancer are presented.
